Floris M, Moschella A, Alcalay M, Montella A, Tirelli M, Fontana L
Hum Genomics. 2024; 18(1):78.
PMID: 38987819
PMC: 11234611.
DOI: 10.1186/s40246-024-00612-w.
Nobakht E, Jagadeesan M, Paul R, Bromberg J, Dadgar S
Transplant Direct. 2021; 7(2):e650.
PMID: 33437865
PMC: 7793397.
DOI: 10.1097/TXD.0000000000001102.
Lauschke V, Zhou Y, Ingelman-Sundberg M
Pharmacol Ther. 2019; 197:122-152.
PMID: 30677473
PMC: 6527860.
DOI: 10.1016/j.pharmthera.2019.01.002.
Gupta P
Indian J Pharm Sci. 2015; 77(2):135-41.
PMID: 26009644
PMC: 4442460.
DOI: 10.4103/0250-474x.156543.
Spielmann N, Wong D
Oral Dis. 2010; 17(4):345-54.
PMID: 21122035
PMC: 3056919.
DOI: 10.1111/j.1601-0825.2010.01773.x.
Salivary gland reaction to phenylbutazone.
Mirsky S
Can Med Assoc J. 2010; 102(1):91-104.
PMID: 20311548
PMC: 1946540.
Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.
Ozdemir V, Suarez-Kurtz G, Stenne R, Somogyi A, Someya T, Kayaalp S
OMICS. 2009; 13(1):43-61.
PMID: 19290811
PMC: 2727354.
DOI: 10.1089/omi.2009.0011.
Genomic medicine: a new frontier of medicine in the twenty first century.
Kumar D
Genomic Med. 2008; 1(1-2):3-7.
PMID: 18923923
PMC: 2276886.
DOI: 10.1007/s11568-007-9003-8.
Pharmacogenomics: challenges and opportunities.
Roden D, Altman R, Benowitz N, Flockhart D, Giacomini K, Johnson J
Ann Intern Med. 2006; 145(10):749-57.
PMID: 17116919
PMC: 5006954.
DOI: 10.7326/0003-4819-145-10-200611210-00007.
Pharmacogenetics, pharmacogenomics and ecogenetics.
Motulsky A, Qi M
J Zhejiang Univ Sci B. 2006; 7(2):169-70.
PMID: 16421980
PMC: 1363768.
DOI: 10.1631/jzus.2006.B0169.
Genome-wide discovery of loci influencing chemotherapy cytotoxicity.
Watters J, Kraja A, Meucci M, Province M, McLeod H
Proc Natl Acad Sci U S A. 2004; 101(32):11809-14.
PMID: 15282376
PMC: 511056.
DOI: 10.1073/pnas.0404580101.
A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients.
Higham C, Aarons L, Holt P, Lynch M, Rowland M
Br J Clin Pharmacol. 1981; 12(2):123-9.
PMID: 7306426
PMC: 1401862.
DOI: 10.1111/j.1365-2125.1981.tb01190.x.
The effect of malnutrition on the pharmacokinetics of phenylbutazone.
Krishnaswamy K, Ushasri V, Naidu N
Clin Pharmacokinet. 1981; 6(2):152-9.
PMID: 7214778
DOI: 10.2165/00003088-198106020-00005.
Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.
Penno M, Vesell E
J Clin Invest. 1983; 71(6):1698-709.
PMID: 6863539
PMC: 370374.
DOI: 10.1172/jci110924.
Sex-related differences in drug disposition in man.
Wilson K
Clin Pharmacokinet. 1984; 9(3):189-202.
PMID: 6375930
DOI: 10.2165/00003088-198409030-00001.
Assessment of methods to identify sources of interindividual pharmacokinetic variations.
Vesell E, Penno M
Clin Pharmacokinet. 1983; 8(5):378-409.
PMID: 6194927
DOI: 10.2165/00003088-198308050-00002.
Effect of age and sex on human drug metabolism.
OMalley K, Crooks J, Duke E, Stevenson I
Br Med J. 1971; 3(5775):607-9.
PMID: 5569980
PMC: 1798743.
DOI: 10.1136/bmj.3.5775.607.
Genetic control of phenylbutazone metabolism in man.
Whittaker J, Evans D
Br Med J. 1970; 4(5731):323-8.
PMID: 5528753
PMC: 1819708.
DOI: 10.1136/bmj.4.5731.323.
Metabolism of drugs.
Br Med J. 1970; 1(5699):767-8.
PMID: 5443374
PMC: 1699689.
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy.
Alexanderson B, Evans D, Sjoqvist F
Br Med J. 1969; 4(5686):764-8.
PMID: 5391106
PMC: 1630282.
DOI: 10.1136/bmj.4.5686.764.
